

About the TIMI Study Group

Since its inception in 1984, the principal goal of the TIMI Study Group has been to conduct high quality clinical trials that enhance the care of patients suffering from cardiovascular disease and its risk factors. TIMI has led a wide array of phase 1 to phase 4 trials, as well as registries. These have ranged in size from less than 30 to 30,000 subjects. The interventions studied include fibrinolytic, antithrombotic, anti-platelet, anti-ischemic, lipid lowering, anti-inflammatory, and anti-diabetic agents as well as percutaneous coronary intervention. In addition, the TIMI Study Group has used its growing database of more than 400,000 subjects and their clinical findings, electrocardiograms, angiograms, biomarkers, and genotypes to enhance the understanding of cardiovascular disease and its risk factors. An important corollary goal has been to train the next generation of clinical investigators. TIMI is especially proud of these trainees who have assumed leadership positions in leading institutions around the world.



2019 AHA SCIENTIFIC SESSIONS

Investigator Presentation Schedule

NOVEMBER 16 – 18

TIMI Study Group

60 Fenwood Road, Suite 7022
Boston, Massachusetts 02115
617.278.0145 or
1.800.385.4444
TIMI@partners.org
www.timi.org
twitter: @TIMIstudygroup



SATURDAY, NOVEMBER 16TH

Session **ACS Management in 2019 and Beyond**
Moderator **Michelle L O'Donoghue**
Time 9:00 – 10:15 AM
Location Main Event II

Title **Incorporating High-Sensitivity Troponin into Clinical Practice**
Presenter **David A Morrow**
Session ACS Management in 2019 and Beyond
Time 9:17 – 9:29 AM
Location Main Event II

Title **Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58**
Presenter **Thomas A Zelniker**
Session Risk Factors and Biomarkers Associated with CVD in Cardiometabolic Disease
Time 9:30 – 9:40 AM
Location Room 204AB

Session **ACS & Interventional Oral Abstracts**
Moderator **Elliott M Antman**
Time 10:45 AM – 12:00 PM
Location Room 103A

Title **LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of the Anti-Endothelial Lipase Antibody MEDI5884 in Subjects With Stable CAD**
Presenter **Christian T Ruff**
Session Lipid Lowering and the Origins of Cardiovascular Disease
Time 1:30 – 2:00 PM (Poster)
Location Zone 1, Science and Technology Hall

Title **Risk Stratification for Critical Limb Ischemia and Amputation in Patients With Atherosclerosis: Insights From the TRA2P-TIMI 50 Trial**
Presenter **Marc P Bonaca**
Session Trailblazing at the Crossroads of Critical Limb Ischemia and Peripheral Revascularization
Time 1:30 – 2:00 PM (Poster)
Location Zone 4, Science and Technology Hall

Title **The Association of White Blood Cell Count and Bleeding in Acute Coronary Syndrome: An Insight Into the Atlas ACS-TIMI 51 Trial**
Presenter **Fahad Alkhalfan**
Session Biomarkers II
Time 1:30 – 2:00 PM (Poster)
Location Zone 4, Science and Technology Hall

Title **Simple Lab Indicators of Risk and Cardiac Intensive Care Unit Outcomes: Analysis From the Critical Care Cardiology Trials Network**
Presenter **Siddharth M Patel**
Session Metabolic Syndrome and Cardiovascular Disease
Time 1:30 – 2:00 PM (Poster)
Location Zone 1, Science and Technology Hall

Title **Prevalence and Outcomes Associated With Advanced Respiratory Support in Contemporary Cardiac Intensive Care Units: A Critical Care Cardiology Trials Network (CCCTN) Registry Study**
Presenter **Thomas Stephen Metkus**
Session Advances in Translational PAH and RV Dysfunction
Time 1:30 – 2:00 PM (Poster)
Location Zone 2, Science and Technology Hall

Session **Late Breaking Science II: Results for the Ischemia Trials: To Intervene or Not to Intervene**
Moderator & Introduction **Elliott M Antman**
Time 2:00 – 3:15 PM
Location Main Event I

Title **Impact of Lowering LDL-C With Evolocumab on Everyday Cognition in Participants From the FOURIER Trial**
Presenter **Baris Gencer**
Session Integration of Lifestyle, Treatment, and Disease
Time 4:30 – 5:00 PM (Poster)
Location Zone 1, Science and Technology Hall

SUNDAY, NOVEMBER 17TH

Title **Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus**
Presenter **Eri Toda Kato**
Session Circulation: Innovation in Cardiovascular Science and Medicine
Time 7:45 – 8:05 AM
Location Nutter Theatre

Title **Which Management Strategy is Best for Women With MI?**
Presenter **Michelle L O'Donoghue**
Session 10 Questions about Cardiovascular Disease in Women
Time 8:00 – 8:06 AM
Location Terrace Ballroom IV

Title **Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention for Acute Coronary Syndrome**
Discussant **Michelle L O'Donoghue**
Session Late Breaking Science IV: State of the Art Interventional Management for ACS Patients
Time 9:09 – 9:13 AM
Location Main Event I

Title	Use of a Genetic Risk Score to Predict Coronary and Vascular Events and Benefit From Evolocumab Therapy in Patients with Atherosclerotic Disease from the FOURIER Trial
Presenter	Nicholas A Marston
Session	Implementation Science Around the Globe
Time	9:19 – 9:25 AM
Location	Room 112AB

Title	Optimal LDL Reduction in Secondary Prevention
Presenter	Marc S Sabatine
Session	Strategies to Reduce Risk in the Post MI Patient
Time	9:30 – 9:40 AM
Location	Room 103A

Title	Performance of a Genome-Wide Polygenic Risk Score to Predict Coronary Events in Patients With Diabetes Without Prior Myocardial Infarction
Presenter	Nicholas A Marston
Session	Polygenic Risk Scores
Time	10:40 – 10:45 AM
Location	Zone 1, Science and Technology Hall

Session	Aspirin: Who Needs it Anymore?
Moderator	Michelle L O'Donoghue
Time	10:45 AM – 12:00 PM
Location	Nutter Theatre

Title	The Association Between Congestion and Outcomes for Patients Treated With Sacubitril-Valsartan Compared to Enalapril in the PIONEER-HF Trial
Presenter	Marc D Samsky
Session	Acute Decompensated Heart Failure
Time	10:50 – 10:55 AM
Location	Moderated Posters 2, Science and Technology Hall

Title	The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
Presenter	Michelle L O'Donoghue
Session	Sex Differences in CHD and Valvular Disease
Time	12:30 – 1:00 PM (Poster)
Location	Zone 3, Science and Technology Hall

Title	Early Aspirin Use, Rejection, and the Development of Cardiac Allograft Vasculopathy Following Orthotopic Heart Transplantation
Presenter	Brian A Bergmark
Session	Advances in Advanced Therapies
Time	3:00 – 3:30 PM (Poster)
Location	Zone 2, Science and Technology Hall

Title	The Effects of Anacetrapib on Occlusive Vascular Events During Post-Trial Follow-Up of the REVEAL Randomized Trial
Presenter	Emily Sammons
Session	Follow-up of Landmark Trials
Time	4:00 – 4:05 PM
Location	Moderated Posters 1, Science and Technology Hall

Title	Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
Author	Remo H Furtado
Session	Examining Effects of Novel Therapeutic Agents in Diabetes
Time	4:00 – 4:10 PM
Location	Room 204AB

Title	Clinical Practice Patterns in Percutaneous Mechanical Circulatory Support (MCS) for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry
Presenter	David D Berg
Session	Clinical Practice and Outcomes in Heart Failure
Time	4:20 – 4:25 PM
Location	Zone 2, Science and Technology Hall

Title	Performance of a Novel Genetic Risk Score to Identify Residual Risk of Ischemic Stroke in Patients Anticoagulated for Atrial Fibrillation
Presenter	Nicholas A Marston
Session	Best of Stroke Abstracts
Time	6:15 – 6:25 PM
Location	Room 105AB

Title	Cardiogenic Shock Complicating NSTEMACS: Characteristics and Outcome
Presenter	Erin Bohula
Session	Challenges in Non ST Elevation ACS
Time	6:15 – 6:25 PM
Location	Room 103A

Title	The Prognostic Utility of a Plasma Ceramide and Phospholipid-Based Risk Score in Patients After Acute Coronary Syndrome
Presenter	Baris Gencer
Session	George E. Brown Memorial Lecture
Time	6:30 – 6:40 PM
Location	Room 119AB

MONDAY, NOVEMBER 18TH	
Title	Save-the-Brain: Target MAP Should Be 75 mmHg After Cardiac arrest (Pro)
Presenter	Erin Bohula
Session	Transatlantic Perspective on Unanswered Questions in Cardiac Critical Care: Joint AHA/ESC-ACCA
Time	9:53 – 9:58 AM
Location	Room 120A

Title	Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER
Presenter	Baris Gencer
Session	Cardiovascular Vulnerability: New Insights
Time	11:30 AM – 12:00 PM (Poster)
Location	Zone 4, Science and Technology Hall

Title	Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From DECLARE-TIMI 58
Presenter	Thomas A Zelniker
Session	Cardiovascular Vulnerability: New Insights
Time	11:30 AM – 12:00 PM (Poster)
Location	Zone 4, Science and Technology Hall

Title	Prognostic Assessment of the IABP-SHOCK II Risk Score in a Contemporary North American Population From the Critical Care Cardiology Trials Network Registry
Presenter	Carlos L Alviar
Session	Hemodynamics and Functional Capacity in Heart Failure
Time	11:30 AM – 12:00 PM (Poster)
Location	Zone 2, Science and Technology Hall

Title	Prognostic Significance of Left Ventricular Systolic Dysfunction at the Time of NSTEMI in Patients With No Prior History of Heart Failure
Presenter	David D Berg
Session	Optimizing Care for the Most Vulnerable
Time	1:30 – 2:00 PM (Poster)
Location	Zone 4, Science and Technology Hall

Title	Use of Pulmonary Artery Catheters in Cardiac Intensive Care Units: Analysis From the Critical Care Cardiology Trials Network (CCCTN) Registry
Presenter	Bernard S Kadosh
Session	Prognosis and Therapies for Acute Coronary Syndromes II
Time	1:30 – 2:00 PM (Poster)
Location	Zone 4, Science and Technology Hall

Title	State (and the Art) of the Cardiac Intensive Care Unit (CICU)
Presenter	David A Morrow
Session	State (and the Art) of the Cardiac Intensive Care Unit (CICU)
Time	2:00 – 2:11 PM
Location	Room 103A

Title	Efficacy and Safety of Sacubitril/Valsartan in Acute Decompensated Heart Failure in High-Risk Patients in the PIONEER-HF Trial
Presenter	David D Berg
Session	Pharmacological Therapy in HF/Cardiomyopathy: The Next Important Indication or Agent?
Time	2:35 – 2:40 PM
Location	Zone 4, Science and Technology Hall

Title	Building a Career as an Academic Investigator in the CICU
Presenter	Erin Bohula
Session	State (and the Art) of the Cardiac Intensive Care Unit
Time	2:55 – 3:06 PM
Location	Room 103A

Title	Genome-Wide Association Study of Over One Million Participants Identifies 49 Novel Loci Associated With Coronary Artery Disease
Presenter	Krishna G Aragam
Session	Genomic and Epidemiology Mid-Career Research Award and Lecture
Time	3:00 – 3:10 PM
Location	Room 121C

Title	Trimethylamine N-Oxide Levels and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: Data From PEGASUS-TIMI 54 Trial
Presenter	Baris Gencer
Session	Biomarkers: To STEMI and Beyond!
Time	3:45 – 3:55 PM
Location	Room 103A

Title	Timing of Onset of Clinical Benefit with Dapagliflozin in Patients with Heart Failure: An Analysis from the Dapagliflozin And Prevention of Adverse-outcomes In Heart Failure Trial (DAPA-HF)
Presenter	Marc S Sabatine
Session	How Do (or Don't) New Therapies Work to Reduce CVD Risk? Latest from Recent Trials
Time	3:53 – 4:01 PM
Location	Room 103B